Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
NPJ Vaccines
|
December 18, 2020
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, et al.
Vaccine
|
November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
Edward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
Vaccines
|
August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
Vaccines
|
August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Vaccines
|
May 25, 2024
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial
Julie A Ake, Kristopher Paolino, Jack N Hutter, et al.
The Lancet. Infectious Diseases
|
September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
David Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases
|
October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
Daniela Manno, Agnes Bangura, Frank Baiden, et al.
The Lancet. Infectious Diseases
|
September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
Muhammed O Afolabi, David Ishola, Daniela Manno, et al.
Vaccines
|
August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo
Hugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
NPJ Vaccines
|
December 18, 2020
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
Ramon Roozendaal, Jenny Hendriks, Thierry van Effelterre, et al.
Vaccine
|
November 19, 2023
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda
Edward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, et al.
Vaccines
|
August 26, 2023
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, et al.
Vaccines
|
August 29, 2024
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, et al.
Vaccines
|
May 25, 2024
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial
Julie A Ake, Kristopher Paolino, Jack N Hutter, et al.
The Lancet. Infectious Diseases
|
September 16, 2021
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
David Ishola, Daniela Manno, Muhammed O Afolabi, et al.
The Lancet. Infectious Diseases
|
October 23, 2022
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial
Daniela Manno, Agnes Bangura, Frank Baiden, et al.
The Lancet. Infectious Diseases
|
September 16, 2021
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
Muhammed O Afolabi, David Ishola, Daniela Manno, et al.
Vaccines
|
August 29, 2024
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo
Hugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, et al.
Science Translational Medicine
|
April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Page
of 5